menu

The ABCs of CTD-PAH: (A)lgorithms, Team-(B)ased Approach, and (C)ombination Therapy

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The ABCs of CTD-PAH: (A)lgorithms, Team-(B)ased Approach, and (C)ombination Therapy

close
4 chapters
Play All
1.25 credits
75 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

  • Commercial Support

    Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.  

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss the impact that various screening protocols have on CTD-PAH patient outcomes.
    • Outline steps involved in the differential diagnosis of CTD-PAH
    • Formulate comprehensive management plans for patients with CTD-PAH
  • Target Audience

    This educational activity is designed for pulmonologists, cardiopulmonologists, cardiologists, rheumatologists, and other AHPs treating patients with PAH

  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    The following financial relationships have been provided:
    John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA 
    Advisory Board: Bayer and Janssen PH
    Consultant: Vertex 
    Speakers Bureau: Bayer, Janssen PH, United Therapeutics

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: sotatercept and GB002 (seralutinib)

  • Method of Participation

    This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view all four online chapters and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Karen Catino at kcatino@achlcme.org

  • ACHL Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Names and details used in this educational activity have been changed to protect patient privacy.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    John Ryan, MD discusses screening protocols, diagnostic and treatment algorithms, clinical trial evidence, and the vital role of multidisciplinary teams for the management of patients with CTD-PAH in this four-chapter series.

  • Provider(s)/Educational Partner(s)

    ReachMD Healthcare Image

  • Commercial Support

    Supported by an educational grant from Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.  

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss the impact that various screening protocols have on CTD-PAH patient outcomes.
    • Outline steps involved in the differential diagnosis of CTD-PAH
    • Formulate comprehensive management plans for patients with CTD-PAH
  • Target Audience

    This educational activity is designed for pulmonologists, cardiopulmonologists, cardiologists, rheumatologists, and other AHPs treating patients with PAH

  • Accreditation and Credit Designation Statements

    ReachMD Healthcare Image

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    The following financial relationships have been provided:
    John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA 
    Advisory Board: Bayer and Janssen PH
    Consultant: Vertex 
    Speakers Bureau: Bayer, Janssen PH, United Therapeutics

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: sotatercept and GB002 (seralutinib)

  • Method of Participation

    This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view all four online chapters and complete the posttest and evaluation. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Karen Catino at kcatino@achlcme.org

  • ACHL Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Names and details used in this educational activity have been changed to protect patient privacy.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule25 Oct 2021
Webpack App